BRIEF-Ritter Pharma announces Phase 3 plans after end of Phase 2 meeting with FDA on RP-G28
August 18, 2017 at 11:44 AM EDT
* Ritter Pharmaceuticals announces Phase 3 plans after its end of Phase 2 meeting with FDA on RP-G28 for lactose intolerance